NY-CONDECO
12.4.2022 14:32:15 CEST | Business Wire | Press release
Condeco , a global leader in workspace scheduling software, is today announcing new research that reveals the importance of fostering a workplace that understands and respects employee needs, with hybrid work opportunities at its core. Its findings support the understanding that hybrid capabilities lead to greater employee advocacy and happiness at work and show that when it comes to recommending their company, hybrid workers can be the biggest advocates.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220412005267/en/
Allowing for a better work-life balance was identified as one of the biggest benefits of hybrid working through Condeco’s new research, which shows a direct relationship between employee satisfaction and improved mental and emotional well-being. Significantly, more than a third of workers surveyed reported that a hybrid work model has positively impacted their mental and physical health.
“Everyone wants something different out of work, but we can clearly see that almost no one wants to be back in the office full-time,” said Paul Statham, Condeco’s CEO & Founder. “We all know by now that hybrid models are key to ensuring a healthy work-life balance, but how each employer acts on that realization will determine their employees’ fulfillment with their company. No one is suggesting that the office is obsolete, on the contrary, it remains a vital place for employees to collaborate and engage. Business leaders looking to provide the best of both worlds for their employees must find a way to transform their offices from a place employees have to go to a place they want to go.”
“The need to have the right digital tools in place has emerged as one of the most important things to get right for hybrid working,” continued Lynda Lowe, CMO at Condeco. “But different generations have different definitions of what the ‘right tools’ are. This research clearly shows the biggest barriers to hybrid working and the fact that many employees still don’t feel that their company is using the right tools for hybrid working.”
Condeco polled 1,500 of today’s workers to get a pulse on the attitudes towards hybrid work and how these feelings are impacting businesses’ acclimation to the future of the working world. Key findings include:
Hybrid Workers Are Happy Workers – And in Turn, They’re Your Most Loyal Employees
- 62% of respondents said they feel satisfied with their current hybrid work schedule – and fostering a work culture that brings happiness helps employers attract and retain top talent.
- Hybrid workers are employers’ biggest advocates, with 63% saying they would recommend their company as an ideal work destination.
- Nearly half of those back in their offices full-time would like to be more hybrid, which employers struggling with the ‘Great Resignation’ appear not to be considering.
Hybrid Work Has Had a Positive Impact on Mental Health, But There Is Still Room for Improvement
- 34% of respondents feel that hybrid working has had a positive impact on their mental and physical health, with only 11% feeling that it has had a negative effect.
- 69% of hybrid workers agreed that their employer takes into consideration the emotional and mental wellbeing of employees.
- The number one benefit of hybrid working was a better work-life balance, with the lack of a social environment offered by work being the biggest barrier to remote working.
Tech Is the Backbone of Hybrid Work – Yet Only Half of Today’s Employees Have the Right Tools
- Businesses have realized the opportunity of hybrid working – 78% of managers believe their business has been streamlined as a result and 80% trust their employees to get their work done.
- Having the right digital tools was identified as the top need to ensuring hybrid working, but only 51% of employees agree that their company is using the right tools to support flexible work and only 50% of respondents feel their company is open to feedback about their digital tool stack.
- Companies are grappling with how best to bring employees back to the office on a flexible basis. To ensure collaboration and high productivity, employers must consider their workplace tech as the backbone to their strategy.
As part of Condeco’s broader marketing campaign that addresses today’s cultural shift in business, Condeco is today releasing a new film short that shines light on the generational divide that has emerged out of the pandemic, and light-heartedly cements the importance of having an employer that understands and embraces employee needs. You can see the full broadcast here .
To download Condeco’s full survey, complete with additional statistics and methodology, please visit: https://www.condecosoftware.com/modern-workplace/research/attitudes-to-hybrid-working-report-2022/ .
About Condeco
Condeco is the global leader in enterprise level workspace solutions. Our software is designed to equip everyone with the tools they need for a seamless end to end experience in today’s office. By giving people control over flexible work, we deliver the certainty people need, enable the collaboration teams crave, and facilitate the insights on capacity that employers demand. From visitor management to workspace booking to office optimization, we are trusted by over 2000 of the world’s largest companies to realize their future at work.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005267/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
